<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Obstet Gynecol Reprod Biol X</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Obstet Gynecol Reprod Biol X</journal-id><journal-title-group><journal-title>European Journal of Obstetrics &#x00026; Gynecology and Reproductive Biology: X</journal-title></journal-title-group><issn pub-type="epub">2590-1613</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31528854</article-id><article-id pub-id-type="pmc">6742903</article-id><article-id pub-id-type="publisher-id">S2590-1613(19)30127-9</article-id><article-id pub-id-type="doi">10.1016/j.eurox.2019.100094</article-id><article-id pub-id-type="publisher-id">100094</article-id><article-categories><subj-group subj-group-type="heading"><subject>Gynaecology: Oncology</subject></subj-group></article-categories><title-group><article-title>Vaginal endometrial stromal sarcoma: A literature review</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Wu</surname><given-names>Hongwen</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Luo</surname><given-names>Yi</given-names></name><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Yin</surname><given-names>Nanlin</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Gui</surname><given-names>Wenwu</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Cao</surname><given-names>Yi</given-names></name><email>2488705761@qq.com</email><xref rid="aff0010" ref-type="aff">b</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Reproductive Medical Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China</aff><aff id="aff0010"><label>b</label>Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing China</aff><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. <email>2488705761@qq.com</email></corresp><fn id="fn0005"><label>1</label><p id="npar0005">Co-first authors.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>27</day><month>8</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2019</year></pub-date><volume>4</volume><elocation-id>100094</elocation-id><history><date date-type="received"><day>13</day><month>3</month><year>2019</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Authors</copyright-statement><copyright-year>2019</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0005"><p>Vaginal endometrial stromal sarcoma (VESS) is a rare disease. To the best of our knowledge, there have only been a few reported cases in the literature. Therefore, we conducted a literature review to obtain specific knowledge of this disease. Thirteen cases of VESS were found by searching the Medline and EMBASE databases in the English language. The mechanism of VESS may be associated with endometriosis, and its diagnosis largely depends on pathological examination because it has no typical symptoms. Treatment of VESS incorporates surgery, chemotherapy, radiotherapy, and hormonal therapy. Some novel drugs targeting its mechanism may become alternative therapies. Its prognostic factors may include tumor stage and the expression of hormonal receptors.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Vaginal endometrial stromal sarcoma</kwd><kwd>Malignant transformation of endometriosis</kwd><kwd>Vaginal sarcoma</kwd><kwd>Endometrial stromal sarcoma</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>Introduction</title><p id="par0005">Endometrial stromal sarcoma (ESS) is a rare neoplasm, accounting for only 0.2% of all uterine malignancies [<xref rid="bib0005" ref-type="bibr">1</xref>]. It is even less likely to be found in extra-uterine sites such as the vagina. Vaginal ESS (VESS) could easily be misdiagnosed because of its rarity and atypical symptoms, and has a very high risk of recurrence, estimated at 50% [<xref rid="bib0010" ref-type="bibr">2</xref>]. Unfortunately, there are no treatment guidelines available. In order to further our understanding of VESS, we conducted this review.</p></sec><sec id="sec0010"><title>Material and methods</title><p id="par0010">A computerized literature search was performed to identify relevant studies reported in the English language in the Medline and EMBASE databases. Since the terms &#x0201c;high-grade endometrial stromal sarcoma&#x0201d; and &#x0201c;low-grade endometrial stromal sarcoma&#x0201d; have been replaced by &#x0201c;undifferentiated sarcoma&#x0201d;, and &#x0201c;endometrial stromal sarcoma&#x0201d; respectively [<xref rid="bib0015" ref-type="bibr">3</xref>], the following keywords were employed: &#x02018;vaginal endometrial stromal sarcoma&#x02019;,&#x02019; endometriosis malignant transformation&#x02019;, and &#x02018;vaginal sarcoma&#x02019;. A total of 13 cases were found. Their symptoms, diagnosis, treatment, and prognosis were summarized and analyzed in this review.</p></sec><sec id="sec0015"><title>Results</title><p id="par0015">The patients&#x02019; ages ranged from 32 to 57(43+/&#x02212;8.7) years. Their symptoms included vaginal mass (4 patients), vaginal bleeding (7), vaginal discharge (1), pelvic mass (1), and pelvic pain (1). Their FIGO stages ranged from I-IVB, and pathological examination revealed that all cases were low-grade vaginal endometrial stromal sarcoma.</p><p id="par0020">Only four cases had immunohistochemistry results. Three of these cases were positive for estrogen receptor (ER), progesterone receptor (PR), and CD10, and negative for desmin. Further results are shown in <xref rid="tbl0005" ref-type="table">Table 1</xref>. Twelve patients had received surgery (local excision, total abdominal hysterectomy (TAH), or bilateral salpingo-oophorectomy (BSO)). Five had received chemotherapy, three had received radiotherapy, and three had received hormonal therapy. During the follow-up period [32 (9&#x02013;96) months], seven patients had no evidence of disease, three patients died of this disease, two patients were lost to follow-up, and one patient was alive with this disease. The three patients who died had advanced clinical stages (IVA/IVB). Five patients had a documented recurrence, including four with an advanced clinical stage (greater than stage III), and one with stage I. Among them, two patients died; two patients had no evidence of disease, and one patient was alive with disease (<xref rid="tbl0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Clinical pathological details of 13 patients from previous studies.</p></caption><alt-text id="at0335">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">First author</th><th align="left">Age</th><th align="left">symptom</th><th align="left">sites</th><th align="left">Tumor size</th><th align="left">FIGO stage</th><th align="left">Grade</th><th align="left">Treatment</th><th align="left">follow-up length</th><th align="left">Recurrence</th><th align="left">Histochemistry</th><th align="left">Endometriosis</th></tr></thead><tbody><tr><td align="left">1. Wang [<xref rid="bib0105" ref-type="bibr">21</xref>]</td><td align="left">40</td><td align="left">VM,VD</td><td align="left">Left part of<break/>vagina</td><td align="left">5cm</td><td align="left">IVA</td><td align="left">LGESS</td><td align="left">Pelvic external<break/>radiotherapy&#x02009;+&#x02009;hormone therapy</td><td align="left">DOD,12 months</td><td align="left">&#x02013;</td><td align="left">Unknown</td><td align="left">&#x02013;</td></tr><tr><td align="left">2. Wang [<xref rid="bib0105" ref-type="bibr">21</xref>]</td><td align="left">32</td><td align="left">VM</td><td align="left">Right, lower one third<break/>of vagina</td><td align="left">1.5cm</td><td align="left">I</td><td align="left">LGESS</td><td align="left">Local wide<break/>excision +<break/>TAH&#x02009;+&#x02009;BSO</td><td align="left">NED,21 months</td><td align="left">&#x02013;</td><td align="left">Unknown</td><td align="left">&#x02013;</td></tr><tr><td align="left">3. Thomas [<xref rid="bib0030" ref-type="bibr">6</xref>]</td><td align="left">32</td><td align="left">VM</td><td align="left">Right lateral<break/>vaginal wall</td><td align="left">2.5cm</td><td align="left">I</td><td align="left">LGESS</td><td align="left">local exision&#x02009;+&#x02009;TAH&#x02009;+&#x02009;BSO</td><td align="left">NED,3 years</td><td align="left">+</td><td align="left">Unknown</td><td align="left">&#x02013;</td></tr><tr><td align="left">4. Sanverdi [<xref rid="bib0125" ref-type="bibr">26</xref>]</td><td align="left">46</td><td align="left">VB</td><td align="left">posterior fornix</td><td align="left">7cm</td><td align="left">II</td><td align="left">LGESS</td><td align="left">TAH&#x02009;+&#x02009;BSO&#x02009;+&#x02009;partial vaginectomy</td><td align="left">NED,22 months</td><td align="left">&#x02013;</td><td align="left">ER(+), PR(+), CD10(+), desmin (-), and caldesmon (-).</td><td align="left">+</td></tr><tr><td align="left">5. Masand [<xref rid="bib0020" ref-type="bibr">4</xref>]</td><td align="left">52</td><td align="left">pelvic mass</td><td align="left">Pelvis,rouond ligament,vagina</td><td align="left">Unknown</td><td align="left">IVB</td><td align="left">LGESS</td><td align="left">surgical treatment&#x02009;+&#x02009;chemotherapy&#x02009;+&#x02009;radiation therapy</td><td align="left">DOD, 96months</td><td align="left">+</td><td align="left">Unknown</td><td align="left">+</td></tr><tr><td align="left">6. Masand [<xref rid="bib0020" ref-type="bibr">4</xref>]</td><td align="left">51</td><td align="left">unknown</td><td align="left">Vagina</td><td align="left">unknown</td><td align="left">I-II&#x0ff1f;</td><td align="left">LGESS</td><td align="left">surgical treatment</td><td align="left">Lost follow-up</td><td align="left">Unknown</td><td align="left">Unknown</td><td align="left">&#x02013;</td></tr><tr><td align="left">7. Masand [<xref rid="bib0020" ref-type="bibr">4</xref>]</td><td align="left">40</td><td align="left">VB</td><td align="left">Vagina,pelvis</td><td align="left">Unknown</td><td align="left">III</td><td align="left">LGESS</td><td align="left">surgical treatment&#x02009;+&#x02009;hormone therapy&#x02009;+&#x02009;chemotherapy</td><td align="left">AWD, 9months</td><td align="left">+</td><td align="left">Unknown</td><td align="left">&#x02013;</td></tr><tr><td align="left">8. Masand [<xref rid="bib0020" ref-type="bibr">4</xref>]</td><td align="left">44</td><td align="left">VB</td><td align="left">Vagina,colon</td><td align="left">unknow</td><td align="left">IVA</td><td align="left">LGESS</td><td align="left">Surgical treatment&#x02009;+&#x02009;chemotherapy</td><td align="left">DOD,36months</td><td align="left">+</td><td align="left">Unknown</td><td align="left">+</td></tr><tr><td align="left">9. Masand [<xref rid="bib0020" ref-type="bibr">4</xref>]</td><td align="left">49</td><td align="left">Pelvic pain and VB</td><td align="left">Ovary,uterine serosa,vagina,urinary bladder,colon,hypogastric LN</td><td align="left">Unknown</td><td align="left">IVB</td><td align="left">LGESS</td><td align="left">surgical treatment&#x02009;+&#x02009;hormone therapy&#x02009;+&#x02009;chemotherapy</td><td align="left">NED,84months</td><td align="left">+</td><td align="left">Unknown</td><td align="left">+</td></tr><tr><td align="left">10. Liu [<xref rid="bib0075" ref-type="bibr">15</xref>]</td><td align="left">32</td><td align="left">VB</td><td align="left">middle and upper segments of the right posterior vaginal wall</td><td align="left">1cm</td><td align="left">I</td><td align="left">LGESS</td><td align="left">hysterectomy, unilateral salpingo-oophorectomy (right) and partial vaginectomy&#x02009;+&#x02009;chemotherapy</td><td align="left">NED,18months</td><td align="left">&#x02013;</td><td align="left">serum AFP, CA125, CA199, CEA, HCG were all negative. CD10(+), ER(+), PR(+), Vimentin (+); desmin(-), muscle actin(-), S-100 protein(-)</td><td align="left">&#x02013;</td></tr><tr><td align="left">11. Corpa [<xref rid="bib0130" ref-type="bibr">27</xref>]</td><td align="left">40</td><td align="left">VM</td><td align="left">Vaginal nodule</td><td align="left">2cm</td><td align="left">I</td><td align="left">LGESS</td><td align="left">local excision</td><td align="left">NED,38months</td><td align="left">&#x02013;</td><td align="left">CD10(+), ER(+),PR(+), Desmin(-), muscle actin(-),<break/>S-100 protein(-), cytokeratin stains(-)</td><td align="left">&#x02013;</td></tr><tr><td align="left">12. Ross [<xref rid="bib0135" ref-type="bibr">28</xref>]</td><td align="left">57</td><td align="left">VB</td><td align="left">Vaginal apex</td><td align="left">8cm</td><td align="left">II</td><td align="left">LGESS</td><td align="left">Local excision&#x02009;+&#x02009;radiotherapy</td><td align="left">Unknown</td><td align="left">Unknown</td><td align="left">Unknown</td><td align="left">+</td></tr><tr><td align="left">13. Kondi [<xref rid="bib0140" ref-type="bibr">29</xref>]</td><td align="left">45</td><td align="left">VB</td><td align="left">Posterior vaginal wall</td><td align="left">2cm</td><td align="left">II</td><td align="left">LGESS</td><td align="left">Local excision</td><td align="left">NED,36 months</td><td align="left">&#x02013;</td><td align="left">Vementine(+)</td><td align="left">Unknown</td></tr></tbody></table><table-wrap-foot><fn><p>VM, vaginal mass. VD, vaginal discharge. H, hysterectomy. BSO, bilateral salpingo-oophorectomy. DOD, die of disease. NED, no evidence of disease. AWD, alive with disease. TAH, total abdominal hysterectomy.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0020"><title>Discussion</title><p id="par0025">VESS has a high rate of recurrence. The rate of recurrence in our study was 38.5%. Clinically, symptoms of ESS are atypical. The diagnosis of VESS depends on pathological examination after excluding metastatic endometrial stromal sarcoma. Its treatment varies in different medical centers.</p><p id="par0030">Endometriosis may be one mechanism of VESS [<xref rid="bib0020" ref-type="bibr">4</xref>]. It has been estimated that almost 1% of endometrioses may become malignant [<xref rid="bib0025" ref-type="bibr">5</xref>], with 25% of endometriosis-related malignancies found in areas outside the ovaries such as the recto-vaginal septum or abdominal wall [<xref rid="bib0030" ref-type="bibr">6</xref>], and 3.6%&#x02013;11.1% of these malignancies detected in the vagina [<xref rid="bib0035" ref-type="bibr">7</xref>]. Vaginal mass and vaginal bleeding were common initial symptoms. Because of its atypical symptoms, pathological examination was the main basis of VESS diagnosis. Furthermore, it must be diagnosed after excluding metastatic endometrial stromal sarcoma [<xref rid="bib0040" ref-type="bibr">8</xref>]. VESS is mostly low-grade endometrial stromal sarcoma. Microscopically, it reveals bland oval cells surrounding arterioles resembling endometrial spiral arterioles with no nuclear atypia or pleomorphism (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>) [<xref rid="bib0010" ref-type="bibr">2</xref>]. The histological morphology of VESS is very similar to some other tumors. Therefore, a comprehensive analysis of multiple immunohistochemical markers, such as desmin, SMA, CD34, CD117, Ki67, VIM, EMA, BCL2, CK, S100, caldesmon, calponin, CD10, ER, PR, STAT6, CD99, and cyclin D is needed to differentiate it from other disease. In low-grade endometrial stromal sarcoma, ER, PR, CD10, and vimentin are usually positive (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>) [<xref rid="bib0015" ref-type="bibr">3</xref>,<xref rid="bib0045" ref-type="bibr">9</xref>]. When there is epithelial differentiation, CK is usually positive, and when there is smooth muscle differentiation, muscle markers are usually positive. Genetic testing is a promising tool in the diagnosis of ESS, especially for those tumors which lack typical morphologic features. It was reported that the JAZFl&#x000b7;SUZl2 fusion gene was positive in 30.8&#x0ff05; of low-grade ESS cases, and the YWHAE-FAM22 fusion gene was positive in 12.5&#x0ff05; of high-grade ESS cases [<xref rid="bib0050" ref-type="bibr">10</xref>]. This genetic testing could also be applied in the diagnosis of VESS.<fig id="fig0005"><label>Fig. 1</label><caption><p>Vaginal endometrial stromal sarcoma. (a) A cellular neoplasm composed of bland oval cells surrounding arterioles resembling endometrial spiral arterioles (hematoxylin and eosin stain, *200 magnification). (b) A higher magnification microphotograph showing the spindle cells surrounding a blood vessel (hematoxylin and eosin stain,*400 magnification).</p></caption><alt-text id="at0325">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><fig id="fig0010"><label>Fig. 2</label><caption><p>Immunohistochemical staining of tumor cells. Immunohistochemical staining (&#x000d7;100) shows that the tumor cells were positive for CD10 (A), estrogen receptor (B), progesterone receptor (C) and vimentin (D).</p></caption><alt-text id="at0330">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="par0035">Because of the rarity of VESS, there is no consensus on its treatment. Treatment often follows the guidelines for uterine ESS. For those with early stage disease or fertility requirements, excision of local lesions is usually performed. It was reported that one patient with uterine ESS achieved a successful pregnancy after hysteroscopic resection of the tumor [<xref rid="bib0055" ref-type="bibr">11</xref>]. For those with advanced clinical stage disease, TAH and BSO are usually performed. However, whether or not to retain the ovaries was controversial in premenopausal women. Some experts argued that BSO should be performed on all patients, while others felt that ovarian-sparing surgery was safe in young patients at early disease stages according to a population-based analysis of ESS. Furthermore, BSO did not appear to affect the time to recurrence or overall survival in stage I low-grade ESS [<xref rid="bib0025" ref-type="bibr">5</xref>,<xref rid="bib0060" ref-type="bibr">12</xref>].</p><p id="par0040">Adjuvant therapy incorporated radiotherapy, chemotherapy, and hormonal therapy. Some argued that surgery and radiotherapy was the most effective treatment for ESS [<xref rid="bib0065" ref-type="bibr">13</xref>], while others thought that radiotherapy could only prevent local recurrence but was not beneficial for survival rate [<xref rid="bib0065" ref-type="bibr">13</xref>]. In our study, three patients (Nos. 1,5,12) received radiotherapy. Among them, two died due to advanced stage disease (Nos. 1,5) and one (No. 12) with early stage disease was lost to follow-up.</p><p id="par0045">Chemotherapy drugs in ESS included cyclophosphamide, cisplatin, ifosfamide, epirubicin, and others [<xref rid="bib0070" ref-type="bibr">14</xref>]. In our study, oxaliplatin, docetaxel [<xref rid="bib0075" ref-type="bibr">15</xref>], and gemcitabine alone or in combination with docetaxel [<xref rid="bib0020" ref-type="bibr">4</xref>] were used. However, the effect of these drugs was not carefully evaluated. In our study, five patients (Nos. 5, 7-10) had single-agent or combined chemotherapy. Four (Nos. 5,7,8,9) of them had a recurrence. Finally, two of them (Nos. 1,8) died, two (Nos. 9,10) had no evidence of disease, and one (No. 7) was alive with disease.</p><p id="par0050">Hormonal therapy was reported to have a favorable survival outcome in ER/PR positive ESS [<xref rid="bib0080" ref-type="bibr">16</xref>]. Mizuno reported three out of six patients with residual or recurrent ESS had a partial response after six months of hormonal therapy [<xref rid="bib0085" ref-type="bibr">17</xref>]. Yamazaki reported a higher response rate was attained with hormonal therapy (85.7%) in 11 ESS patients with initial recurrence of disease [<xref rid="bib0070" ref-type="bibr">14</xref>]. Hormonal therapy was also used as an alternative treatment for patients with fertility requirements. One woman with uterine ESS delivered a live-born male neonate at 34 gestational weeks. The patient had been on megestrol acetate therapy for 8 years before cessation to achieve pregnancy. She was then referred to a reproductive endocrinologist to hasten conception but achieved spontaneous pregnancy [<xref rid="bib0090" ref-type="bibr">18</xref>]. In our study, 3 out of 13 patients received hormonal therapy. One patient (No. 1) with stage IV disease died. One patient (No. 7) was alive with stage III disease, and one (No. 9, stage IVB) had no evidence of disease.</p><p id="par0055">Some drugs targeting mechanisms of ESS could be novel treatment methods which could also be applied in VESS. Endometriosis is connected with angiogenesis, lymphangiogenesis, and neurogenesis, which is related to inflammation [<xref rid="bib0095" ref-type="bibr">19</xref>]. Mizuno evaluated the effects of long-term, high-dose medroxyprogesterone with aspirin and observed no thromboembolic complications over a median duration of 63 months [<xref rid="bib0085" ref-type="bibr">17</xref>]. Although the role of aspirin in preventing endometriosis-related malignancy was not evaluated in this study, it may have some effect due to its anti-inflammatory action. Since unopposed estrogens, type II diabetes, and obesity are risk factors of malignant transformation of endometriosis [<xref rid="bib0100" ref-type="bibr">20</xref>,<xref rid="bib0105" ref-type="bibr">21</xref>], and the insulin and insulin-like growth factor-I receptor family could stimulate DNA synthesis and cell proliferation, anti-insulin resistance drugs might help reduce the risk of malignant transformation of endometriosis [<xref rid="bib0055" ref-type="bibr">11</xref>]. Because follicle-stimulating hormonal receptor (FSHR) is reported to be expressed selectively on the surface of blood vessels in soft tissue sarcomas including ESS [<xref rid="bib0110" ref-type="bibr">23</xref>], FSHR could be a potential target for tumor imaging examination and therapy [<xref rid="bib0110" ref-type="bibr">23</xref>]. Low-grade ESS is often associated with JAZF1-SUZ12 (formerly JAZF1-JJAZ1) fusion gene re-arrangement and Wnt signaling [<xref rid="bib0115" ref-type="bibr">24</xref>]. Overexpression of the JAZF1-SUZ12 fusion protein in 293&#x02009;T cells could destabilize Polycomb Repressive Complex 2 and decrease histone methyltransferase activity through the Wnt pathway. Therefore, exploring drugs that target the Wnt pathway may lead to a promising treatment.</p><p id="par0060">In our study, patients who died of VESS all had advanced stage disease (Nos. 1,5,8), which was consistent with Ngan&#x02019;s study [<xref rid="bib0120" ref-type="bibr">25</xref>]. Therefore, tumor stage seems to be a prognostic factor of VESS. Hormonal receptors such as ER and PR were expressed in more than half of the ESS tissues in Park&#x02019;s study of 51 patients, and positive hormonal receptors were significantly associated with improved overall survival [<xref rid="bib0085" ref-type="bibr">17</xref>]. In our study, three patients with positive ER and PR had no evidence of disease. Therefore, hormonal receptor expression could be another prognostic factor of VESS.</p></sec><sec id="sec0025"><title>Conclusion</title><p id="par0065">VESS is a very rare disease without typical symptoms. Pathological examination is needed in order to make an accurate diagnosis. Surgery is highly recommended, and different adjuvant therapies should be adopted cautiously because of their inconclusive roles. Conservative surgery plus adjuvant hormonal therapy may be a good choice for patients at early disease stages, especially for women with fertility requirements. Exploring drugs according to the mechanism of the disease could lead to other treatment options. Tumor stage and expression of hormonal receptors may be prognostic factors of this disease. Further studies are needed because of the limited number of reported VESS cases.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0075">The authors declare no conflict of interest.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Puliyath</surname><given-names>G.</given-names></name><name><surname>Nair</surname><given-names>V.R.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Endometrial stromal sarcoma</article-title><source>Indian J Med Pediatr Oncol</source><volume>31</volume><issue>Jan. (1)</issue><year>2010</year><fpage>21</fpage><lpage>23</lpage></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Zaza</surname><given-names>K.J.</given-names></name><name><surname>Arafah</surname><given-names>M.A.</given-names></name><name><surname>Al-Badawi</surname><given-names>I.A.</given-names></name></person-group><article-title>Vulvar extrauterine endometrial stromal sarcoma: a case report and literature review</article-title><source>Hematol Oncol Stem Cell Ther</source><volume>8</volume><issue>Sep. (3)</issue><year>2015</year><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">25585306</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name></person-group><article-title>Endometrial stromal sarcoma arising in vagina</article-title><source>Int J Clin Exp Pathol</source><volume>6</volume><issue>12</issue><year>2013</year><fpage>2997</fpage><lpage>3002</lpage><pub-id pub-id-type="pmid">24294390</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Masand</surname><given-names>R.P.</given-names></name><name><surname>Euscher</surname><given-names>E.D.</given-names></name><name><surname>Deavers</surname><given-names>M.T.</given-names></name><name><surname>Malpica</surname><given-names>A.</given-names></name></person-group><article-title>Endometrioid stromal sarcoma: a clinicopathologic study of 63 cases</article-title><source>Am J Surg Pathol</source><volume>37</volume><issue>Nov. (11)</issue><year>2013</year><fpage>1635</fpage><lpage>1647</lpage><pub-id pub-id-type="pmid">24121169</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>R.C.</given-names></name><name><surname>Dash</surname><given-names>R.</given-names></name><name><surname>Bentley</surname><given-names>R.C.</given-names></name><name><surname>Snyder</surname><given-names>M.J.</given-names></name><name><surname>Haney</surname><given-names>A.F.</given-names></name><name><surname>Robboy</surname><given-names>S.J.</given-names></name></person-group><article-title>Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types</article-title><source>Int J Gynecol Pathol</source><volume>20</volume><issue>Apr. (2)</issue><year>2001</year><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">11293158</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Ulbright</surname><given-names>T.M.</given-names></name><name><surname>Kraus</surname><given-names>F.T.</given-names></name></person-group><article-title>Endometrial stomal tumors of extra-uterine tissue</article-title><source>Am J Clin Pathol</source><volume>76</volume><issue>Oct. (4)</issue><year>1981</year><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">7293962</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>C.</given-names></name><name><surname>Pizer</surname><given-names>E.</given-names></name><name><surname>Veljovich</surname><given-names>D.S.</given-names></name><name><surname>Drescher</surname><given-names>C.W.</given-names></name><name><surname>Peters</surname><given-names>W.A.</given-names><suffix>3rd</suffix></name><name><surname>Paley</surname><given-names>P.J.</given-names></name></person-group><article-title>Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis</article-title><source>Gynecol Oncol</source><volume>103</volume><issue>Dec. (3)</issue><year>2006</year><fpage>1130</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">16996119</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Rivard</surname><given-names>C.</given-names></name><name><surname>Carter</surname><given-names>J.S.</given-names></name><name><surname>Downs</surname><given-names>L.S.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Low-grade endometrial stromal sarcoma primarily arising in the vagina: a case report</article-title><source>J Reprod Med</source><volume>60</volume><issue>Sep.&#x02013;Oct. (9&#x02013;10)</issue><year>2015</year><fpage>433</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">26592071</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Rauh-Hain</surname><given-names>J.A.</given-names></name><name><surname>del Carmen</surname><given-names>M.G.</given-names></name></person-group><article-title>Endometrial stromal sarcoma: a systematic review</article-title><source>Obstet Gynecol</source><volume>122</volume><issue>Sep. (3)</issue><year>2013</year><fpage>676</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">23921879</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>L.X.</given-names></name><name><surname>Tu</surname><given-names>X.Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.F.</given-names></name><name><surname>Bi</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>W.T.</given-names></name></person-group><article-title>Endometrial stromal sarcoma: morphologic features and detection of JAZF1-SUZ12 and YWHAE-FAM22 fusion genes</article-title><source>Chin J Pathol</source><volume>45</volume><issue>5</issue><year>2016</year><fpage>308</fpage><lpage>313</lpage></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Koskas</surname><given-names>M.</given-names></name><name><surname>Morice</surname><given-names>P.</given-names></name><name><surname>Yazbeck</surname><given-names>C.</given-names></name><name><surname>Duvillard</surname><given-names>P.</given-names></name><name><surname>Walker</surname><given-names>F.</given-names></name><name><surname>Madelenat</surname><given-names>P.</given-names></name></person-group><article-title>Conservative management of low-grade endometrial stromal sarcoma followed by pregnancy and severe recurrence</article-title><source>Anticancer Res</source><volume>29</volume><issue>Oct. (10)</issue><year>2009</year><fpage>4147</fpage><lpage>4150</lpage><pub-id pub-id-type="pmid">19846964</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W.Y.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Choi</surname><given-names>C.H.</given-names></name><name><surname>Kang</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>T.J.</given-names></name><name><surname>Bim</surname><given-names>B.G.</given-names></name></person-group><article-title>Low-grade endometrial stromal sarcoma: a single center&#x02019;s experience with 22 cases</article-title><source>Int J Gynecol Cancer</source><volume>18</volume><issue>5</issue><year>2008</year><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">18179547</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Weitmann</surname><given-names>H.D.</given-names></name><name><surname>Knocke</surname><given-names>T.H.</given-names></name><name><surname>Kucera</surname><given-names>H.</given-names></name><name><surname>Potter</surname><given-names>R.</given-names></name></person-group><article-title>Radiation therapy in the treatment of endometrial stromal sarcoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>49</volume><issue>Mar. (3)</issue><year>2001</year><fpage>739</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">11172957</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>H.</given-names></name><name><surname>Todo</surname><given-names>Y.</given-names></name><name><surname>Mitsube</surname><given-names>K.</given-names></name><name><surname>Hareyama</surname><given-names>H.</given-names></name><name><surname>Shimada</surname><given-names>C.</given-names></name><name><surname>Kato</surname><given-names>H.</given-names></name></person-group><article-title>Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study</article-title><source>J Gynecol Oncol</source><volume>26</volume><issue>3</issue><year>2015</year><fpage>214</fpage><pub-id pub-id-type="pmid">25925291</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Endometrial stromal sarcoma with endometrioid adenocarcinoma of the uterus: a case report</article-title><source>Int J Clin Exp Pathol</source><volume>8</volume><issue>5</issue><year>2015</year><fpage>5242</fpage><lpage>5246</lpage><pub-id pub-id-type="pmid">26191224</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name><name><surname>Baek</surname><given-names>M.-H.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>Y.-T.</given-names></name><name><surname>Nam</surname><given-names>J.-H.</given-names></name></person-group><article-title>Investigation of hormonal receptor expression and its prognostic value in endometrial stromal sarcoma</article-title><source>Virchows Arch</source><volume>473</volume><issue>1</issue><year>2018</year><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">29869299</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>M.</given-names></name><name><surname>Yatabe</surname><given-names>Y.</given-names></name><name><surname>Nawa</surname><given-names>A.</given-names></name><name><surname>Nakanishi</surname><given-names>T.</given-names></name></person-group><article-title>Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma</article-title><source>Int J Clin Oncol</source><volume>17</volume><issue>Aug. (4)</issue><year>2012</year><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">21830086</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>A.A.</given-names></name><name><surname>Gubbels</surname><given-names>A.L.</given-names></name><name><surname>Remmenga</surname><given-names>S.</given-names></name><name><surname>Tomich</surname><given-names>P.</given-names></name><name><surname>Molpus</surname><given-names>K.</given-names></name></person-group><article-title>Successful pregnancy after fertility-sparing local resection and uterine reconstruction for low-grade endometrial stromal sarcoma</article-title><source>Obstet Gynecol</source><volume>120</volume><issue>Aug. (2 Pt. 2)</issue><year>2012</year><fpage>486</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">22825274</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Higashiura</surname><given-names>Y.</given-names></name><name><surname>Shigetomi</surname><given-names>H.</given-names></name><name><surname>Kajihara</surname><given-names>H.</given-names></name></person-group><article-title>Pathogenesis of endometriosis: the role of initial infection and subsequent sterile inflammation (Review)</article-title><source>Mol Med Rep</source><volume>9</volume><issue>1</issue><year>2014</year><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">24173432</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Zanetta</surname><given-names>G.M.</given-names></name><name><surname>Webb</surname><given-names>M.J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Keeney</surname><given-names>G.L.</given-names></name></person-group><article-title>Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis</article-title><source>Gynecol Oncol</source><volume>79</volume><issue>1</issue><year>2000</year><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11006024</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.-T.</given-names></name><name><surname>Wang</surname><given-names>D.-B.</given-names></name><name><surname>Liu</surname><given-names>K.-R.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>C.-X.</given-names></name><name><surname>Guo</surname><given-names>C.-S.</given-names></name></person-group><article-title>Inducing malignant transformation of endometriosis in rats by long-term sustaining hyperestrogenemia and type II diabetes</article-title><source>Cancer Sci</source><volume>106</volume><issue>1</issue><year>2015</year><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">25421527</pub-id></element-citation></ref><ref id="bib0110"><label>23</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Renner</surname><given-names>M.</given-names></name><name><surname>Goeppert</surname><given-names>B.</given-names></name><name><surname>Siraj</surname><given-names>M.A.</given-names></name><name><surname>Radu</surname><given-names>A.</given-names></name><name><surname>Ghinea</surname><given-names>N.</given-names></name></person-group><article-title>Follicle-stimulating hormonal receptor expression in soft tissue sarcomas</article-title><source>Histopathology</source><volume>63</volume><issue>Jul. (1)</issue><year>2013</year><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">23659266</pub-id></element-citation></ref><ref id="bib0115"><label>24</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Przybyl</surname><given-names>J.</given-names></name><name><surname>Kidzinski</surname><given-names>L.</given-names></name><name><surname>Hastie</surname><given-names>T.</given-names></name><name><surname>Debiec-Richter</surname><given-names>M.</given-names></name><name><surname>Nusse</surname><given-names>R.</given-names></name><name><surname>van de Rijn</surname><given-names>M.</given-names></name></person-group><article-title>Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway</article-title><source>Gynecol Oncol</source><volume>149</volume><issue>May (2)</issue><year>2018</year><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">29544705</pub-id></element-citation></ref><ref id="bib0120"><label>25</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Ngan</surname><given-names>H.Y.</given-names></name><name><surname>Fisher</surname><given-names>C.</given-names></name><name><surname>Blake</surname><given-names>P.</given-names></name><name><surname>Shepherd</surname><given-names>J.H.</given-names></name></person-group><article-title>Vaginal sarcoma: the Royal Marsden experience</article-title><source>Int J Gynecol Cancer</source><volume>4</volume><issue>Sep. (5)</issue><year>1994</year><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">11578429</pub-id></element-citation></ref><ref id="bib0125"><label>26</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Sanverdi</surname><given-names>I.</given-names></name><name><surname>Temizkan</surname><given-names>O.</given-names></name><name><surname>Vural</surname><given-names>F.</given-names></name><name><surname>Koc</surname><given-names>N.</given-names></name><name><surname>Polat</surname><given-names>M.</given-names></name></person-group><article-title>Primary vaginal endometrial stromal sarcoma associated with endometriosis: a case report with a review of the literature</article-title><source>Eur J Gynaecol Oncol</source><volume>3</volume><issue>7</issue><year>2016</year><fpage>717</fpage><lpage>721</lpage></element-citation></ref><ref id="bib0130"><label>27</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Corpa</surname><given-names>M.V.</given-names></name><name><surname>Serafini</surname><given-names>E.P.</given-names></name><name><surname>Bacchi</surname><given-names>C.E.</given-names></name></person-group><article-title>Low-grade endometrial stromal sarcoma presenting as vaginal nodule</article-title><source>Ann Diagn Pathol</source><volume>8</volume><issue>5</issue><year>2004</year><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">15494937</pub-id></element-citation></ref><ref id="bib0135"><label>28</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Berkowitz</surname><given-names>R.S.</given-names></name><name><surname>Ehrmann</surname><given-names>R.L.</given-names></name><name><surname>Knapp</surname><given-names>R.C.</given-names></name></person-group><article-title>Endometrial stromal sarcoma arising from vaginal endometriosis</article-title><source>Obstet Gynecol</source><volume>51</volume><year>1978</year><fpage>34s</fpage><lpage>37s</lpage><pub-id pub-id-type="pmid">618472</pub-id></element-citation></ref><ref id="bib0140"><label>29</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Kondi-Paphitis</surname><given-names>A.</given-names></name><name><surname>Smyrniotis</surname><given-names>B.</given-names></name><name><surname>Liapis</surname><given-names>A.</given-names></name><name><surname>Kontoyanni</surname><given-names>A.</given-names></name><name><surname>Deligeorgi</surname><given-names>H.</given-names></name></person-group><article-title>Stromal sarcoma arising on endometriosis. A clinicopathological and immunohistochemical study of 4 cases</article-title><source>Eur J Gynaecol Oncol</source><volume>19</volume><issue>6</issue><year>1998</year><fpage>588</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">10215449</pub-id></element-citation></ref></ref-list></back></article>